(PUB) Investing 2015

July 2015

Morningstar FundInvestor

5

Data through June 30, 2015 T. Rowe Price Blue Chip Growth

Ticker

Status Yield Total Assets

Mstar Category

TRBCX Open

0.0% $28,902 mil

Large Growth

Morningstar Analyst Rating 06-17-15

Investment Style Equity Stock %

Historical Profile Return Risk Rating High Above Avg Highest

100% 99% 99% 99% 99% 100% 99% 99% 99%

„

Manager Change Partial Manager Change

14.0 18.0 22.8

Morningstar Pillars Process Performance

Growth of $10,000

Positive Positive Positive Positive Positive

Investment Values of Fund Investment Values of S&P 500

10.0

People Parent Price

7.0

Performance Quartile (within Category) History

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 06-15

Morningstar Analyst Rating Morningstar evaluates mutual funds based on five key pillars, which its analysts believe lead to funds that are more likely to outperform over the long term on a risk-adjusted basis. Analyst Rating Spectrum Œ „ ´ˇ ¨

30.92 9.25 -1.63 2.95 0.56 8.69

32.68

35.73 9.73 -6.06 0.66 0.40 9.33

40.23

23.01

32.77 42.57 16.11

38.13 16.42 1.36 -0.29 0.06 16.36

38.65 1.50 -0.61 -1.14 0.13 1.37

45.63 18.41

64.60 41.57

67.27 9.28 -4.41 -3.77 0.00 9.28 0.00 3.26 0.72 -0.02 60

71.63

NAV

5.95 1.04 0.69 0.26 5.69 0.08 0.00 0.85 0.28 53

-42.62 13.02

6.48 5.25 2.52 0.00 6.48 0.00 0.00 16

Total Return %

7.53 1.21 0.42

-5.62 -4.18 0.17

2.41 3.15 0.35

9.18 8.09 0.00

+/-S&P 500

5.36 0.15

+/-Russ 1000Gr Income Return % Capital Return %

-42.79 12.60

42.42

18.06

41.57

36

25

48

69

20

39

17

18

7

Total Rtn % Rank Cat

Pillar Spectrum Positive

0.16 0.00 0.88 0.56

0.13 0.00 0.81 0.36

0.15 0.00 0.77 0.42

0.07 0.00 0.80 0.22

0.04 0.00 0.81 0.15

0.02 0.00 0.77 0.08

0.05 0.00 0.77 0.12

0.14 0.00 0.76 0.32

0.00 0.00 0.74 0.03

Income $

§ Negative

¶ Neutral

Capital Gains $ Expense Ratio % Income Ratio % Turnover Rate % Net Assets $mil

. . .

Performance 06-30-15 1st Qtr 2nd Qtr

3rd Qtr

4th Qtr

Total 1.50

32

44

39

32

54

60

47

44

24

35

32

2011 2012 2013 2014 2015

5.74 0.72 -13.52 10.20

7,236

7,998

11,296 8,811

6,727

25,806 23,276 20,230 13,692 10,597 10,970 9,461

18.76 -5.45 6.34 -0.83 18.41 8.15 3.69 11.94 12.78 41.57 -1.10 4.16 1.73 4.27 9.28 5.96 . . . .

Portfolio Analysis 03-31-15 Share change since 12-14 Total Stocks:133 Sector

Rating and Risk Time Load-Adj

PE Tot Ret% % Assets

Morningstar

Morningstar Risk vs Cat

Morningstar Risk-Adj Rating

Period Return % Rtn vs Cat

Amazon.com Inc

Cnsmr Cyc

39.87 4.35

.

1 Yr 3 Yr 5 Yr

12.95 20.21 20.30

Trailing

Total

+/-

+/- Russ %Rank Growth of

Biogen Inc

Hlth care 29.1 19.00 3.01 Hlth care 29.9 8.53 2.90 Cnsmr Cyc 25.1 0.98 2.89 Technology 83.3 9.93 2.67 Technology 25.8 -0.85 2.59 Finan Svs 30.0 2.81 2.53

Return% S&P 500 1000Gr

Cat

$10,000

High High +Avg

+Avg +Avg

McKesson Corp Priceline Group Inc Facebook Inc Class A Google Inc Class C Capit

3 Mo 6 Mo 1 Yr

0.49 0.21 6.48 5.25 12.95 5.53 20.21 2.90 20.30 2.96 9.68 1.79 4.99 0.63

0.37 2.52 2.39 2.22 1.71 0.58 2.80

52 10,049 16 10,648 17 11,295 10 17,371 4 25,196 16 25,193 22 20,760

10 Yr Incept

9.68

Avg

10.44

3 Yr Avg 5 Yr Avg 10 Yr Avg 15 Yr Avg

Visa Inc Class A Danaher Corp

Other Measures

Standard Index

Best Fit Index S&P 500 Mstar Large Growth

Industrl

23.7 0.18 2.49

MasterCard Inc Class A

Finan Svs 28.8 8.87 2.39

Alpha

2.8

0.9

Actavis PLC

Hlth care

17.89 2.28

.

Beta

0.99

1.03

Apple Inc

Technology 15.6 14.53 2.18 Hlth care 13.4 24.67 2.15 Technology 26.8 1.77 2.12 Hlth care 39.5 3.46 2.07 Technology 33.2 -12.67 2.05 Hlth care 61.7 -2.30 1.98 Basic Mat 30.1 5.06 1.92

R-Squared

69

89

Tax Analysis Tax-Adj Rtn% %Rank Cat Tax-Cost Rat %Rank Cat 3 Yr (estimated) 5 Yr (estimated) 10 Yr (estimated) 19.72 5 0.41 16 19.99 3 0.26 14 9.49 11 0.18 12 Potential Capital Gain Exposure: 43% of assets

Gilead Sciences Inc Google Inc Class A

Standard Deviation

10.22 20.21

Celgene Corp Baidu Inc ADR

Mean

Sharpe Ratio

1.86

Alexion Pharmaceuticals Sherwin-Williams Co American Airlines Group American Tower Corp Boeing Co

Morningstar’s Take by Katie Rushkewicz Reichart, CFA 06-17-15 T. Rowe Price Blue Chip Growth has excelled during manager Larry Puglia’s 22-year tenure, supporting its Morningstar Analyst Rating of Silver.

Industrl Industrl Real Est

17.3 8.12 1.65 8.7 -25.16 1.63 48.1 -4.75 1.61

nearly twice the benchmark and near its all-time high. Chinese Internet names such as Baidu, Tencent, and Alibaba have also been a favorite area for the fund, providing some non-U.S. exposure. Meanwhile, it has limited exposure to benchmark stalwart Apple AAPL, a move that at times has weighed on performance. The fund occasionally stumbles in market pullbacks, and it’s lost a bit more than the Russell 1000 Growth Index in down markets during the past decade. Certain positioning, such as its above-average biotech stake, could weigh on results if there’s an industrywide sell-off. Longer term, there’s also the question of capacity across T. Rowe’s large-growth funds (this strategy alone is $50 billion in assets). However, on the whole the fund has done a good job of producing strong risk-adjusted results for investors during Puglia’s tenure. Reasonable costs also help the case for this Silver-rated fund.

Current Investment Style

Sector Weightings

% of Stocks

Rel S&P 500 High

3 Year Low

Market Cap % Giant 46.5 Large 44.8 Mid 8.6 Small 0.0 Micro 0.0 Avg $mil: 56,163

Value Blnd Growth

Beyond benefiting from an experienced manager, the fund draws on T. Rowe’s analyst team for stock ideas, which has proved quite capable at finding successful large-growth names. The fund has consistently produced strong returns relative to Morningstar Category peers and the Russell 1000 Growth Index, even in recent years when it’s been difficult for many active-equity managers to beat passive index funds. Puglia looks for companies with sustainable earnings, free cash flow growth, and management teams that will drive further growth. While the fund’s active share (its differentiation from the benchmark) isn’t exceptionally high, the fund makes enough bets to meaningfully distinguish itself from a performance standpoint. In recent years, that’s included a significant stake in health-care stocks, which has boosted results. The fund held 11% of assets in biotech as of March,

Large Mid Small

Cyclical 38.72 BasicMat 3.63 CnsmrCyc23.52 FinanSvs 9.95 Real Est 1.62 Sensitive 33.99 CommSrvs 1.11 Energy 1.71 Industrl 13.67 Technlgy 17.50 Defensive27.29 CnsmrDef 1.84 Hlthcare 25.45 Utilities 0.00

. .

h r t y u j i o p a k s d f

5 4

. 28 20 . 14 10

2 2

. . . .

2 0 5 2

Value Measures Price/Earnings Price/Book Price/Sales Price/Cash Flow Dividend Yield % Long-Term Erngs Book Value Sales Cash Flow Historical Erngs Growth Measures

Rel Category

22.91 4.54 1.92 8.44 0.76 15.80 10.89 11.16 11.81 21.69

1.28 1.58 1.06 0.84 0.58 1.18 1.06 1.39 0.91 0.98

. 16 14 . 22 15

. .

4 2

. 25 13 . . .

% Rel Category

Composition - Net

Cash 0.8 Stocks 99.2 Bonds 0.0 Other 0.0 Foreign 9.9

Address:

T. Rowe Price Blue Chip Growth Fund, Inc Baltimore, MD 21202 800-638-5660

Minimum Purchase: Min Auto Inv Plan:

$2500 $2500

Add: $100 IRA: $1000

Add: $100

Profitability

% Rel Category

Sales Fees:

No-load

Return on Equity Return on Assets Net Margin

21.73 9.85 14.98

1.04 1.01 1.06

Web Address: Inception: Advisor: Subadvisor: NTF Plans:

www.troweprice.com

Management Fee:

0.30% mx./0.26% mn., 0.15%A Mgt:0.57% Dist: .

(% of Stock)

06-30-93

Actual Fees:

T. Rowe Price Associates, Inc.

Expense Projections: Income Distribution:

3Yr:$230 Annually

5Yr:$401 10Yr:$894

None

N/A

Mutual Funds ß ®

© 2015Morningstar, Inc.All rights reserved. The information herein isnot representedorwarranted tobe accurate, correct, completeor timely.Pastperformance isnoguaranteeof future results.Accessupdated reports at To order reprints, call 312-696-6100. mfb.morningstar.com.

EQ